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 Duchenne muscular dystrophy (DMD) is an X-linked genetic disorder which causes 
muscle degeneration leading to loss of ambulation, cardiac dysfunction, respiratory 
complications, and premature death. The DMD gene is the largest gene within the human 
genome, and thus has a diverse mutational profile which prevents many corrective therapies 
from reaching a large patient cohort. My goal was to determine the feasibility of a new 
CRISPR/Cas9-based gene editing technique known as Homology Independent Targeted 
Integration (HITI) in replacing segments of the DMD gene. By replacing large segments of the 
DMD gene, a larger patient cohort could potentially be encompassed by a single therapy. As a 
proof of principle, I tested whether small (~1 kb) and medium sized (~175 kb) replacements 
were feasible at the 5ʹ end of the DMD gene using a HITI-mediated replacement with previously 
validated Cas9 guide RNAs (gRNAs). Genomic DNA PCR was used to detect the expected 
knock-in while sequencing confirmed that the integration was seamless with no insertion or 
deletions (indels). I then optimized this system by altering the molecular ratios of the two HITI 
gene editing components (CRISPR/Cas9 and HITI donor DNA plasmid) and found that a 1:1 
ratio was optimal. Based on these studies, small and medium HITI replacements are feasible 
within the DMD gene, thus a large HITI replacement (~715 kb) of DMD exons 41-55 (which 
would potentially correct ~37% of patients) was designed. This consisted of two plasmids 
encoding i) Cas9 with a GFP reporter and ii) a HITI donor DNA with the coding sequence (CDS) 
of DMD exons 41-55, two gRNAs, and an RFP reporter. Knock in of the CDS of DMD exons 41-
55 was detected and analyzed by genomic DNA PCR and Sanger sequencing. As with the 
proof-of-concept studies, the DMD exon 41-55 CDS was seamlessly integrated in place of the 
natural DMD exon 41-55 locus. These studies lay the groundwork for development of a HITI-
mediated gene correction therapy that could potentially restore full-length dystrophin in a large 
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Chapter 1: Background 
 
1.1 Dystrophin and Duchenne Muscular Dystrophy 
 Duchenne muscular dystrophy (DMD) is an X-linked genetic disorder caused by myriad 
mutations within the DMD gene which contains a total of 79 exons and codes for the 427 kDa 
muscle isoform of the dystrophin protein (Fig. 1).1 Dystrophin is a structural protein which serves 
to reinforce the plasma membrane via a connection between cytoskeletal actin filaments and 
the dystroglycan complex (DGC) (Fig. 1A).2 As such, dystrophin has several key domains 
including an N-terminal actin binding domain, a central rod domain comprised of spectrin-like 
 
Fig. 1 (A) Schematic of the axis of force transduction in muscle cells. Dystrophin links the cytoskeletal actin to the 
transmembrane dystroglycan complex thus linking the cytoskeleton to the extracellular matrix via laminin. (B) 
Schematic of the dystrophin protein with the major domains labeled. (C) DMD gene diagram of exons corresponding 
to each domain in dystrophin. The shape of each exon depicts reading frame phasing, while red boxes show 
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repeats with a second actin binding domain, and a C-terminal domain that directly interacts with 
the DGC (Fig. 1B).2 Dystrophin acts as a shock-absorber during normal muscle contraction and 
is required to prevent muscle damage and degeneration during normal activity.2 In the absence 
of dystrophin, muscle degeneration leads to weakness which eventually progresses to a loss of 
ambulation in the early teens.1 Once in a wheelchair, patients have steep declines in cardiac 
and respiratory function (due to the involvement of the heart and diaphragm, respectively) which 
are the primary causes of the early mortality characteristic of DMD.1 
The DMD gene has a diverse mutational profile, due in part to the size of the gene.3 
Single Nucleotide point mutations, which is the result of single base pair changes in the DNA 
sequence, account for about 10.5% of DMD causing mutations.3 Exonic duplications account for 
about 10.9% of DMD mutations and occur when a portion of the gene is duplicated and placed 
directly adjacent to the original gene fragement.3 Exonic deletions are when a portion of the 
gene containing one or more exons is fully excised from the gene, and account for about 68.5% 
of DMD mutations.3 Both exonic deletions and duplications usually result in frameshift mutations 
that generally lead to loss of functional dystrophin protein. Another 6.9% of DMD mutations 
consist of subexonic insertions and deletions (indels) that also generally result in frameshift 
mutations.3 Another 2.7% of DMD mutations consist of mutations that affect the splice sites of 
certain exons.3 The final 0.5% of mutations consist of variable and highly specific mutations 
throughout the intronic regions of the DMD gene.3 Despite this extensive mutational profile, 
gene editing has shown great potential in correcting many of the types of mutations described 
above.  
 
1.2 CRISPR/Cas9 Gene Editing 
Clustered Regularly Interspaced Short Palindromic 
Repeats and the associated protein 9 (CRISPR/Cas9) is an 
adaptive immune system found in bacteria that utilizes an 
RNA-programmable endonuclease to protect bacteria 
against viral invaders. This system, which consists of a 
guide RNA (gRNA) and a Cas9 endonuclease protein, has 
been repurposed to make precise double stranded breaks 
(DSBs) at a site complementary to the gRNA and near a 
short recognition sequence known as a protospacer 
adjacent motif (PAM) site (Fig. 2). 
 
 
Fig. 2 Depiction of Cas9 targeting via the 
use of a gRNA complementary to a 
portion of genomic DNA. The genomic 
DNA bound by the gRNA is shown in red. 
In blue is the PAM site. The SaCas9 














There are several different homologs of the Cas9 protein from different bacteria which 
have differences in size and PAM recognition sequence. The most well characterized variant is 
Cas9 from streptococcus pyogenes (SpCas9) which is encoded by 1,371 amino acids and has a 
PAM recognition sequence of 5ʹ-NGG-3ʹ.4-6 A less commonly used Cas protein is from 
staphylococcus aureus (SaCas9) which, in contrast to SpCas9, is encoded by 1,053 amino 
acids and has a PAM recognition sequence of 5ʹ-NNGRRT-3ʹ.7 The use of the smaller SaCas9 
protein is preferable in virally delivered gene therapies on account of the limited cargo space 
(~5 kb) associated with viral vectors such as the Adeno-Associated Virus (AAV).8 
  
1.3 Current and Future Clinical Approaches to DMD 
 
1.3.1 Current Approaches 
There is currently no cure for DMD. The contemporary treatment paradigm states that 
patients with DMD should be started on corticosteroids as soon as possible, which has been 
shown to increase the duration of ambulation by 2 to 4 years.9 There is also some evidence that 
the heart benefits from early use of corticosteroids.10 Current recommendations indicate that an 
ACE inhibitor or an angiotensin receptor blocker (ARB) should be started before the age of ten 
to prevent cardiac degeneration and subsequent dysfunction in patients with DMD.11 Patients 
are eventually bound to a wheelchair as they lose their ability to walk, and due to the 
involvement of the diaphragm, patients will experience respiratory decline and will eventually 
require the use of a ventilator.1 
 
1.3.2 Gene replacement therapies 
One commonly used methodology for the correction of genetic disease in which there is 
a lack of functional protein is to deliver the coding sequence (CDS) of the protein with a tissue-
specific promotor to ensure it is expressed only in the appropriate tissues.12-14 AAV is the most 
common delivery system used for gene replacement in humans, but it’s packaging limit is small 
(~5 kb), thus preventing delivery of the complete dystrophin CDS of ~11 kb. Instead, delivery of 
synthetic, miniaturized isoforms of dystrophin which lack non-essential domains has been 
shown to improve symptoms in DMD animal models and is currently being tested in human 
trials.14,15 Despite this promising approach, the long-term benefits of miniaturized dystrophin 





1.3.3 Exon skipping and reframing 
 Another method for correcting certain DMD-causing mutations is to induce exon skipping 
during pre-mRNA maturation with antisense oligonucleotides to restore a coherent reading 
frame. Two phosphorodiamidate morpholino oligomer (PMO) drugs have been approved that 
utilize this method which are eteplirsen and golodirsen which induce skipping of exons 51 and 
53, respectively, potentially benefiting a combined 22% of patients.16,17 The restoration of 
dystrophin and subsequent therapeutic benefit of PMOs are exceedingly low and would require 
weekly treatments to maintain therapeutic benefits.18 Thus, there is a need for more robust 
therapies.  
 Recently, it has been shown that gene editing can be used to reframe mutant DMD 
genes with higher efficiency and potentially more long-term benefits. The most notable example 
is with exclusion of exon 51 which was demonstrated in a DMD dog model.19 This approach 
targets the 3ʹ splice elements to introduce inactivating mutations that result in exon 51 exclusion 
during pre-mRNA maturation. This results in a truncated, mutant form of dystrophin for which 
the long term benefits have not been adequately characterized, once again showing the need 
for a therapy that would restore full-length dystrophin.19 This approach also suffers from being 
highly specific towards one type of DMD mutation that only has the potential to help a specific 
subset of the patient population (~13%), therefore a novel therapy that would be capable of 
correcting a wider range of mutations is needed.  
 
1.3.4 Efforts to restore full-length dystrophin 
 Homology Directed repair (HDR) is the classically used method for integration of a 
desired DNA sequence into a genome and has been used to attempt restoration of the full-
length dystrophin CDS, and thus full-length protein.20,21 This methodology works by providing a 
donor DNA molecule encoding a knock-in sequence flanked by long regions of sequence 
homologous to the genomic context on either side of a DNA break induced by a nuclease (e.g. 
Cas9). The large homologous sequences drive the HDR DNA repair pathway over other DNA 
repair pathways in many proliferative cell types.22 One study used this to induce knock-in of 
exon 44 in mutated induced pluripotent stem cells (iPSCs) that were derived from DMD patients. 
Although this correction was highly efficient, iPSCs are expected to poorly recapitulate the 
cellular environment of mature, non-proliferative muscle cells.20 Another study attempted to 
correct a nonsense mutation within exon 53 in a mouse model by means of HDR using a dual-
gRNA CRISPR/Cas9 approach and a donor containing the corrected exon 53 via an 
intramuscular injection into the tibialis anterior muscle.23 Despite there being some evidence of 
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successful HDR, there was exceedingly low efficiency (~0.18% of total genomes) depicting a 
lack of potential for HDR to be used for an in vivo gene therapy and necessitating the design of 
a novel and more efficient method of knock-in for non-proliferating cells.23  
 
 
1.4. Homology Independent Targeted Integration 
 
Though HDR works well for integration in some cells, it has notoriously low efficiency in 
non-proliferating cell types such as muscle fibers, where the non-homologous end-joining 
(NHEJ) DNA repair pathway predominates.21,24 Recently, a method was described which 
accomplishes high efficiency knock in using the NHEJ pathway called Homology-Independent 
Targeted-Integration (HITI).25 HITI requires two components; i) CRISPR/Cas9 and ii) a donor 
DNA containing CRISPR/Cas9 cut sites flanking the desired knock-in fragment (Fig.3).25 
CRISPR/Cas9 generates a genomic DNA break while also cleaving the donor DNA and 
activating it as a NHEJ substrate for integration into the genome DSB. HITI was initially 
designed with a single target site and has been utilized to knock in a missing exon in Mertk, the 
gene implicated in a rat model of retinitis pigmentosa.25 The HITI treated rats showed improved 
eye function when compared to their untreated or HDR treated counterparts.25 This same study 
used mice to show that the in vivo efficiency of systemic AAV-mediated HITI knock-in of a 
reporter gene to be ~10% in the quadriceps muscle and ~3-4% in heart muscle.25 This HITI 
approach shows the potential to be therapeutically beneficial as a gene therapy, and despite its 
apparent low efficiency, shows much more promise than the previously used HDR method of 
knock-in gene correction, especially in non-proliferating cells.25 HITI also remains un-optimized, 
allowing for further improvements. Thus, this strategy could theoretically be used for the 





Chapter 2: Feasibility Studies for HITI Exon Replacement 
 
2.1 Introduction 
The previously described HITI methodology has been utilized not only for the insertion of 
missing exons and reporter genes at a single site, but also for the replacement of small (~1.3 
kb) portions of the CCAT1 gene in human cancer cells.26 To ensure that a similar approach 
would work at the DMD locus, previously validated gRNAs targeting up- and down-stream of 
exon 2 were utilized to remove this exon and subsequently knock in an exogenous DNA 
sequence (Fig. 3A). I also sought to determine whether larger replacements were feasible using 
HITI. To this end, a set of previously validated gRNAs, one upstream of exon 2 and one 
downstream of exon 3 were utilized in a deletion and subsequent HITI experiment to confirm the 
feasibility of larger genomic replacements than previously described (Fig. 3B). 
Fig. 3 Schematic showing the HITI strategy for (A) exon 2 replacement and (B) exon 2 + 3 replacement. Proper 
cleavage at the two genomic loci and of the knock in fragment can result in one of three possible outcomes. Simple 
deletion of the flanked exon(s), inverse integration of the knock in fragment, or proper forward knock in. Inverse 





For the replacement of exon 2 (small replacement, ~1 kb), two gRNAs flanking this exon 
were utilized to cut within the genome as well as the HITI donor vector. The cut sites on the 
donor vector were engineered to be the reverse complement of those cut sites in the genomic 
context and placed at opposite 5ʹ and 3ʹ ends of one another (Fig. 3A). This was done so that in 
the case of inverse integration of the HITI donor fragment, the Cas9 cut sites would be 
reconstituted, allowing for re-cleavage and a greater proportion of integrations being in the 
forward orientation (Fig. 3A). A similar strategy was used for the replacement of exons 2 and 3 
(medium replacement, ~175 kb) with a gRNA targeting upstream of exon 2 and one 
downstream of exon 3 as well as a similarly designed HITI donor fragment (Fig. 3B). 
These experiments utilized a “triple plasmid system” wherein one plasmid had encoded 
the exogenous knock-in donor DNA sequence flanked by two gRNA cut sites, and two 
additional plasmids encoded SaCas9 and the two gRNAs utilized in cutting the genomic DNA 
and the donor plasmid.   
 
2.2 Materials and Methods 
2.2.1 Molecular Cloning 
 Generation of the plasmids used in these studies was accomplished through several 
different traditional and modern cloning techniques. For the swapping of gRNAs, a technique 
known as restriction free cloning (RFC), which utilizes PCR to amplify the entire plasmid with 
two mega-primers that contain the desired change flanked by two regions of complementarity to 
DNA context surrounding the change, was used. All other cloning was accomplished with the In-
Fusion cloning kit (Takara Bio) according to the manufacturer’s recommendations.  
 
2.2.2 Cell culture and treatments 
 Human embryonic kidney 293 (HEK293) cells were cultured in HEK complete medium 
(Dulbecco’s modified Eagle medium high glucose supplemented with 10% cosmic calf serum, 
1% 100X antifungal/antimicrobial and 1% 100X modified Eagle medium non-essential amino 
acids) in 10 cm2 dishes until they were ~80-90% confluent. They were then dissociated from the 
dishes using 0.025% trypsin-EDTA and counted with a hemacytometer. Cells were plated in 
each well of a 12-well dish (200,000 cells/well) and allowed to grow for one day before being 
used for experimentation. Cells were cultured at 37°C with 100% humidity and 5% CO2.  
 Transfection of cells with plasmid DNA was accomplish with the use of Lipofectamine 
LTX per the manufacturer’s recommendations with the indicated amount of DNA, 5 µL of 
Lipofectamine LTX, and 1 µL of Plus Reagent per µg DNA. Once transfected, cells incubated for 
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6 hours before the medium was replaced with fresh HEK complete medium. Cells were cultured 
for three days before extraction of genomic DNA for analysis.  
 
2.2.3 Genomic DNA PCR analysis 
 Polymerase Chain Reaction (PCR) was performed using Q5 high-fidelity 2X master mix 
per the manufacturer’s recommendations with the indicated primers and addition of 0.08 U/µL of 
Q5 Hot Start High-Fidelity DNA Polymerase. PCR products were resolved using electrophoresis 
on either 1% agarose-TAE or 10% polyacrylamide-TBE gels as indicated and stained with 
ethidium bromide. Images were collected using a BioRad ChemiDoc Imaging System with 
automatic optimal exposure times. The primers utilized for the PCR differed by assay. In the 
assay performed in chapter 2.3.2 the 5ʹ end amplicon was generated with a forward primer that 
anneals upstream of the 5ʹ Cas9 cut site and a reverse primer that anneals within the knock-in 
fragment. The 3ʹ end amplicon was generated with a forward primer that anneals within the 
knock-in fragment and a reverse primer that anneals downstream of the 3ʹ Cas9 cut site. Finally, 
in section 2.3.3, the bulk amplicon was generated by the 5ʹ forward primer and the 3ʹ reverse 
primer from the previous assay, which encompasses the entire knock-in. Primer Tm’s were 
calculated based on NEB’s Q5 DNA polymerase 2X master-mix online suggestions and the 
extension time was calculated based on the amplicon length, utilizing 30 seconds per kilobase 
of amplicon.  
 
2.2.4 EnGen Mutation Detection Assay 
 The EnGen mutation detection assay from NEB used for the confirmation of active 
gRNAs makes use of the T7 endonuclease I (T7E1) enzyme to cleave at mismatched DNA. To 
begin, genomic DNA PCR was used to generate amplicons surrounding the expected site of 
editing. These amplicons were gel purified and subsequently incubated at 95°C followed by 
slow annealing at a ramp speed of -0.1°C/second to allow for the reannealing of heterogeneous 
DNA indicative of editing. Next, the T7E1 enzyme was added to the reannealed DNA and 
allowed to incubate at 37°C for 15 minutes. The resulting cleaved DNA was analyzed via 
polyacrylamide gel electrophoresis (PAGE) stained with ethidium bromide.  
 
2.3 Results and Discussion 
 
2.3.1 Exon 2 and 3 targeting gRNAs 
 Prior to the experiments performed in this study, gRNAs targeting exons 2 and 3 were 
designed de novo by first identifying SaCas9 PAM sequences (5ʹ-NNGRRT-3ʹ) within 1000 base 
pairs (bp) of the targeted exon as deletion and duplication mutations that affect a given exon 
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have a higher probability of also including the surrounding intronic sequence that is closest to 
the exon. Importantly, intronic targeting is preferred because the indels that are common with 
the NHEJ DNA repair pathway are less likely to be deleterious in non-coding regions. It was 
noted in the design of exon 2 targeting gRNAs that upstream targeting sequences tended to 
have much larger off-target profiles likely due to homogeneity of 3ʹ splice elements, thus the 
gRNAs were designed both upstream and downstream of exon 2 while they were only designed 
downstream of exon 3. 
Exclusion criteria were used to ensure optimal candidate gRNAs. Firstly, gRNA 
sequences containing putative RNA polymerase III termination signals (four or more contiguous 
thymidine residues in the coding strand) were excluded as this could lead to pre-mature 
termination during transcription from the U6 promoter. Next, gRNAs with more than 30 predicted 
off-target sites or any number of exonic off-target sites in the human genome as predicted by 
CCTop bioinformatics software were eliminated.27 The predicted off-targets of the remaining 
gRNAs were noted and this information will be utilized to aid in analyzing off-target profiles at a 
later time. Finally, as mismatches between the target DNA and gRNA or suboptimal PAM 
sequences can inhibit gene editing, gRNAs were rejected if their target sequence or PAM 
contained single nucleotide polymorphisms (SNP) or variations (Vars) with greater than one 
percent minor allele frequency based on the ClinVar and dbSNP databases.28,29 
After the initial screening, the candidate gRNAs were cloned into plasmids downstream 
of a U6 promoter along with an SaCas9 expression cassette driven by the cytomegalovirus 
immediate early enhancer and promoter (CMVP) for high-level, constitutive expression. These 
plasmids were used to transfect HEK293 cells to test for efficient cleavage at the expected 
genomic loci. Amplicons were generated from the genomic DNA flanking the sites of expected 
editing and the EnGen mutation detection kit, which makes use of the T7 endonuclease I (T7EI) 
enzyme that cleaves at sites of DNA mismatches, was used to check for proper editing. 
Through this experimentation it was revealed that the lead gRNA candidates for upstream exon 
two targeting was hDSA001, for downstream exon two targeting was hDSA027 and for 
downstream exon three targeting was JHI3012.  
 
2.3.2 HITI Replacement of small and medium sized DMD gene fragments 
 To begin, a DNA fragment already housed within the lab was used to create a HITI 
donor vector which contained the genomic Cas9 cut sites on either end of the knock-in fragment 
as described above (Fig. 3). To test whether or not small and medium sized fragments of the 
DMD gene could be replaced with a HITI donor, HEK293 cells were co-transfected with three 
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plasmids: two containing the SaCas9 expression cassette and the chosen gRNAs, and a HITI 
donor plasmid containing paired gRNA cut sites flanking a GFP expression cassette. The gRNA 
pair for the small replacement was hDSA001 and hDSA027 while the gRNA pair for the medium 
replacement was hDSA001 and JHI3012 (Fig. 3). 
Gel images from genomic DNA PCR for the exon 2 replacement (small replacement of 
~1 kb) revealed that proper integration did occur at the expected locus when using knock-in 
specific primers (Fig. 4A). A similar result was noted for the replacement of exons 2 and 3 
(medium replacement of ~175 kb) using a similar method for PCR (Fig. 4B). For both 
experiments, the expected knock-in bands were not present in cells treated with CRISPR only 
or with donor only showing that these components alone are not sufficient for knock in. The cells 
treated with a combination of CRISPR and a non-template donor (an identical donor lacking the 
Cas9 cut sites) also did not show the expected knock-in bands, confirming that Cas9 cleavage 
of the donor is necessary for HITI knock in to occur. The expected band from the exon 2 and 3 
replacement was extracted and sequenced, confirming a seamless integration at the 5ʹ and 3ʹ 




Fig. 4 Gel images showing successful knock in of the HITI donor following PCR of treated HEK293 genomic DNA 
with knock-in specific primers. This was shown for both (A) exon 2 replacement and (B) exon 2-3 replacement. 
Sequencing data showed that there was perfect joining of (C) the 5ʹ end of the HITI insertion as well as (D) the 3ʹ end 




2.3.3 Optimization of HITI plasmid ratios for small and medium sized replacements                
Next, I wanted to ensure that the optimal ratios of Cas9 plasmid to Donor plasmid were 
being used to get the most deletion and integration events possible. To this end, variable 
amounts of Cas9:Donor plasmid were used to transfect HEK293 cells and subsequently 
screened using the PCR conditions described in section 2.3.2 (Fig. 5A). The experiment with 
decreasing Cas9:Donor ratios was completed with the small replacement and showed that the 
most integration occurred when there was a 1:1 ratio (Fig. 5A). As this was expected to be 
applicable regardless of the size of replacement, it was decided that the experiment with 
increasing Cas9:Donor would be conducted with the medium sized replacement (Fig. 5B). This 
PCR was also conducted with primers flanking the whole knock-in region instead of the knock-in 
specific primers to test whether detection of the entire knock-in locus was possible (Fig. 5B). 
The gel images indicated that the optimal ratio was 1:1 and showed that detection of the whole 
knock-in amplicon was possible, albeit at a lower efficiency than the knock-in specific primers 
(Fig. 5B). I hypothesize this lack of efficiency is due to amplification of the smaller deletion 
amplicon with higher efficiency than the full knock-in amplicon. It was believed that the limiting 
factor in this experimental set-up is the co-delivery of three plasmids, therefore, a dual-plasmid 
system was used for subsequent development of this potential therapeutic strategy.  
 
2.3.4 Conclusions 
 These preliminary experiments depict that the HITI replacement of gene fragments is 
feasible within the DMD gene, both on a small (~1 kb) scale and on a larger (~175 kb) scale via 
the utilization of SaCas9, two gRNAs and a HITI donor fragment that contains the genomic 
 
Fig. 5 Gel images depicting the CRISPR:Donor titration experiments. Results from both (A) increasing the Donor 
amount compared to the CRISPR amount and (B) increasing the CRISPR amount compared to the Donor amount. 




Cas9 cut sites on either end and in the orientation described in section 2.1. This answer allowed 
for the optimization of the ratios of plasmid at 1:1 of Cas9 plasmids to donor plasmid, which 
could prove useful in cases that necessitate the use of a triple plasmid delivery or for the future 





Chapter 3: HITI Replacement of DMD Exons 41-55 
 
3.1 Introduction 
 Using the basic methodology described in chapter 2, I sought to design a large (~715 
kb) HITI-based gene editing strategy that would enable the restoration of full-length dystrophin 
in a greater number of patients. To this end, bioinformatics analysis was done on the DMD gene 
to pick an efficient target for exonic replacement. Exons 41-55 encompass two mutational 
hotspots and efficient replacement of this region could 
benefit ~37% of DMD patients, and thus this was the 
target chosen for this study (Fig. 1C).30 In the case that 
deletion, but not integration, occurs within the region, an 
open reading frame would be maintained creating a 
truncated, potentially therapeutic isoform of dystrophin 
analogous to the synthetic, miniaturized isoforms of 
dystrophin discussed in section 1.3.2. Though the 
excision of 41-55 would truncate two different spectrin-
like repeats, SWISS-MODEL online homology-modelling 
server was used to predict the structure of the resulting 
hybrid spectrin-like repeat that is formed from the joining 
of exons 40 and 56. The predicted hybrid spectrin-like 
repeat modelled on a helical bundle structure similar to 
the endogenous spectrin-like repeat 22 based on global quality estimates (Fig. 6).2,31-35  
 The HITI donor vector was designed such that the CDS of exons 41-55 (~2.5 kb) was 
placed between two regions of ~100 bp of endogenous intronic sequence to include the 5ʹ and 
3ʹ splice elements. Just past the intronic sequence on both sides were placed the genomic cut 
sites, put in the same orientation as described in section 2.1, once again to reduce the 
incidence of inverse integration by reconstituting the Cas9 cut sites (Fig. 7). The two gRNAs 
were included with the HITI donor in one plasmid, allowing for a two-plasmid system wherein 
there was the HITI donor plasmid with two gRNAs and a plasmid containing the SaCas9 
expression cassette.  
 Advantages of this gene editing approach over current therapies include the restoration 
of a full-length dystrophin protein which is an attractive concept due to the known long-term 
consequences of a truncated isoform of dystrophin on the functional outcomes of those affected 
by DMD. Since this approach corrects dystrophin at the genomic level, there is potential for this 
therapy to be a one-time administration as opposed to therapies that require lifelong dosing to 
 
Fig. 6 Homology models of predicted 
structure of (A) the endogenous spectrin-like 
repeat 22 and (B) the hybrid spectrin-like 
repeat produced from joining of exons 40 and 
56 built using SWISS-MODEL. Blue areas 
depict more favorable global quality 
estimates whereas red areas depict less 




have the desired effect. Finally, the advantage of this therapy over other therapies that aim at 
genomic correction is the range of patient cohort that would benefit. Rather than being an 
approach targeted at a specific mutation, this method would effectively correct any mutation 
within the exon 41-55 locus of the DMD gene. 
 There are also some advantages this system has that would potentially enhance the 
therapeutic effect if this strategy gets adapted to humans, the first being the physiology of 
muscle cells. As muscle progenitor cells mature into mature muscle cells, they fuse, creating 
myofibers which are multinucleated. This, in turn, lends itself to a gene editing approach, as a 
small proportion of edited nuclei could have a larger-than-predicted effect. Another advantage is 
the planned delivery method is the adeno-associated virus serotype 9 (AAV9) which has a 
tropism for muscle cells.  
 
3.2 Materials and Methods 
 
3.2.1 Molecular Cloning 
 The plasmids for these experiments were constructed through a variety of cloning 
methods including inverse PCR, wherein primers are used to amplify an entire plasmid except a 
portion that is to be deleted. These linearized DNA fragments were then used with the In-Fusion 
 
Fig. 7 (A) Depiction of the plasmids used for the exon 41-55 HITI replacement strategy with (B) a schematic showing 
the editing outcomes affiliated with this HITI strategy. Red boxes show mutational hotspots within the DMD gene.  
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cloning kit per the manufacturer’s recommendations to create new plasmids.  
 
3.2.2 Cell culture and treatments 
 Culturing of human embryonic kidney 293 (HEK293) cells was accomplished using 
similar methods as those used in section 2.2.2. Transfections were also accomplished using 
Lipofectamine LTX as described in section 2.2.2, however, the plasmids used were different for 
these experiments. The transfections in this chapter also used a dual-plasmid transfection 
system as opposed to the triple plasmid transfection system utilized in the previous chapter.  
 
3.2.3 Fluorescence microscopy 
 Fluorescence microscopy was accomplished by imaging transfected HEK293 cells at 
room temperature on a Nikon Ti2-E inverted widefield system with a Hamamatsu Orca Flash 4.0 
camera. The dimensions of analyzed images were 1022 X 1024 pixels and were scaled such 
that there were 1.63 microns/pixel. The fluorescence images were quantified using a custom 
analysis using the NIS Elements General Analysis 3 module. Cells were identified through 
automated detection of bright spots of any non-negligible signal intensity after background 
correction. The mean intensities of red and green signal were then measured and recorded for 
each bright spot. A threshold based on Otsu methodology was used to differentiate high and low 
signal in each channel, and spots were counted according to their expression category for each 
of the two fluorophores. Percent double-positive was calculated by dividing the number of cells 
with both green and red signal by the total number of cells with both red and green signal, green 
signal alone, and red signal alone and then multiplying the fraction by 100%. 
 
3.2.4 Genomic DNA PCR analysis 
 PCR of extracted HEK293 genomic DNA was accomplished using similar methods as 
those described in section 2.2.3. Key differences include the primers used, and the cycling 
conditions. For the experiments conducted in section 3.3.3, knock-in specific primers were used 
such that a forward primer was utilized upstream of the genomic Cas9 cut site and a reverse 
primer was utilized within the HITI knock in. The Tm’s were once again calculated based on 
NEB’s Q5 DNA polymerase 2X master-mix online suggestions and the extension time was 
calculated based on the amplicon length, once again utilizing 30 seconds for every kilobase that 







3.3 Results and Discussion 
 
3.3.1 Identification of active gRNAs 
Guide RNAs (gRNAs) targeting upstream of exon 41 (JHI40 series) and downstream of 
exon 55 (JHI55 series) were designed as described in 2.3.1. JHI40 series gRNAs targeted 
within intron 40 as close to exon 40 as possible to include a larger patient cohort (including 
those with mutations within intron 40). For the JHI55A series gRNAs, an alternative DMD gene 
promoter exists near the 3ʹ end of intron 55 and drives expression of an important dystrophin 
isoform (Dp116) for Schwann cells.36 To avoid removing this alternative promoter, JHI55A 
gRNAs were designed at the 5ʹ end of intron 55, near exon 55. These gRNAs were cloned into 
plasmids containing an SaCas9 expression cassette driven by the CMVP with the gRNA driven 
by a U6 promoter as with the experiments described in Chapter 2. 
 The plasmids described above were transfected into HEK293 cells to test the editing 
capacity of the gRNAs. It was revealed that there were five gRNAs capable of editing from the 
JHI55A series and three gRNAs were capable of editing from the JHI40 series (Fig. 8). The lead 
candidates chosen for HITI editing were JHI40-008 and JHI55A-004 (Fig. 8). 
 
3.3.2 Co-delivery efficiency  
 Once the lead gRNAs were chosen, they were cloned into the HITI donor plasmid along 
with the appropriate Cas9 cut sites on both sides of the donor, while the SaCas9 expression 
cassette was alone in a separate plasmid. To optimize co-transfection efficiency, the HITI donor 
 
A
JHI55A- 001 003 004 Unt. cont. 005 006 008 009 010 Unt. cont.
+ + + + +- - - - - + + + + +- - - - - +- +-
B
JHI40- 001 002 004 005 006 008 Unt. cont.
+ - + - + - + - + - + - + - + -
Fig. 8 Polyacrylamide gel images of the T7E1 
assay for the (A) JHI55A targeting series and 
(B) the JHI40 targeting series. “Unt.” denotes 
untreated DNA and “cont.” denotes the positive 
control provided with the NEB EnGen Mutation 
Detection kit. Yellow dots denote the expected 
band sizes with editing at the respective target 
site. “+” and “-” denotes reactions with and 
without T7E1 enzyme, respectively. Active 
gRNAs are denoted in green text. 
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plasmid with gRNAs was tagged with a red fluorescence protein (RFP) and the SaCas9 plasmid 
was tagged with a green fluorescence protein (GFP) and these plasmids were used to co-
transfect HEK293 cells using variable amounts of each plasmid at a 1:1 ratio (0.5 µg, 1.0 µg or 
2.0 µg of each plasmid). The cells were imaged using fluorescence microscopy to measure 
efficiency of co-transfection by the co-localization of RFP and GFP and viability by the estimated 
percent cell confluency (Fig. 9). Results indicated that the 1.0 µg treated cells had the best co-
transfection efficiency with 31.40% double-positive cells, 2.0 µg treated cells had lower 
efficiency at 25.10% double-positive cells, and the 0.5 µg cells had the lowest efficiency with 
only 7.62% double-positive cells (Fig. 9).  
 
3.3.3 Detection of HITI knock in with the dual-plasmid system 
I next wanted to determine whether the dual-plasmid system resulted in proper HITI 
knock in. Using genomic DNA extracted from the 1.0 µg treated cells described in 3.3.2, PCR 
was performed using knock-in specific primers. The results showed successful integration of the 
HITI donor in the CRISPR and Donor treated cells (Fig. 10A). The CRISPR only treatment and 
Donor only treatment did not have the expected knock-in band, once again showing that both 
components are necessary for HITI mediated knock in (Fig. 10A). The untreated cells also did 
not show the expected knock in band, confirming the lack of knock-in band within the 
 
Fig. 9 Fluorescence microscopy images showing co-transfections of the two HITI plasmids with the percentage of 
double-positive cells compared to the total amount of counted cells. 
Green Channel Red Channel Multi-Channel
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1.0 µg of each 
plasmid







endogenous genome (Fig. 10A). The knock-in band was sequenced, and this revealed 
seamless integration (Fig. 10B).   
 
3.3.5 Conclusions 
 These experiments began by designing and confirming gRNAs that targeted an excision 
of exons 41 through 55, which were subsequently used in experiments for the replacement of 
those exons using HITI gene editing. The amount of DNA to be transfected was subsequently 
optimized in HEK293 cells with the new dual-plasmid HITI system to be 1.0 µg. The resulting 
genomic DNA was utilized in a PCR which showed the successful integration of the HITI donor 
into the genome. These experiments lay the groundwork for the development of a therapy that 
has the potential to restore full-length dystrophin while simultaneously reaching a diverse array 
of DMD-causing mutations.   
 
Fig. 10 (A) Gel image showing the successful knock in of the HITI donor at the 41-55 site using a 5ʹ knock-in specific 
primer set. (B) Sanger sequencing chromatogram depicting seamless integration of the HITI donor sequence based 





Chapter 4: Future Directions 
4.1 Quantitative Measure of Editing 
The immediate next step for this project is to get a robust quantitative measure of the 
editing efficiency in dual-plasmid transfected cells. To this end I would suggest the use of 
quantitative PCR (qPCR) with TaqMan technology which would enable a robust quantification of 
the different editing outcomes and the total amount of DMD loci. Different primer/probe pairs 
would be generated for each editing outcome and the total DMD loci, and with these numbers, 
the editing efficiency could be estimated. 
There are also other methods of quantification that could be useful such as digital 
dropwise PCR (ddPCR) which works similarly to a qPCR but makes use of dividing the PCR 
reaction into small oil droplets and then quantitating based on the presence of fluorescence or 
not. This quantitation method, though requiring a more involved workflow, has advantages in 
that it gives an absolute quantification instead of a quantification based on a standard curve, 
and also has the ability to detect very low abundance loci in case that is needed.  
 
4.2 Use of cells Derived from DMD Patients 
The Flanigan lab has an extensive cell bank containing modified human fibroblast cells 
derived from DMD patients. These fibroblast cells have been engineered with lentivirus for 
tetracyline-inducible MyoD expression cassette, which induced differentiation of the fibroblasts 
into myoblasts and, subsequently, myotubes. Testing the above-performed HITI experiments in 
these cells would more closely recapitulate the editing environment that would be present within 
a DMD patient’s cells while simultaneously enabling assays to assess expression of the HITI-
edited locus. Reverse transcription PCR (RT-PCR) and western blotting could be used to check 
for correction of the DMD mRNA transcript and restoration of dystrophin protein, respectively, 
while qPCR could be used to quantify the editing at the genomic and mRNA level. 
Immunofluorescence staining could be used to check for proper localization of dystrophin within 
the cells.  
 
4.3 Development of DMD HITI Editing for In Vivo Experiments 
An important step in translating a therapy from the lab into the clinic is showing it works 
in animal models. Importantly, there exists an animal model of DMD that has the human 
dystrophin gene with mutations existing in the region I am targeting. The presence of a 
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humanized mouse model is important for my purposes due to the fact that the intronic regions 
are not homologous between mouse and human, rendering the gRNAs designed for human 
cells unable to target Cas9 to the specific places within the genome targeted within humans. 
With the humanized version of the DMD gene, this once again makes it possible to target the 
region of interest with the designed gRNAs.  
 To prepare for in vivo experiments, an appropriate vector must be chosen, and 
preparations must be made to use the vector decided upon. The vector we have preliminarily 
chosen is the viral vector known as AAV9. This vector was chosen on account of its efficiency 
and its tropism for muscle, allowing for more robust delivery to the targeted cells than other 
vectors. To prepare for the use of AAV, the gene fragments from the Cas9 plasmid and the HITI 
donor plasmid would need to be cloned into a vector containing the inverted terminal repeat 
(ITR) regions that are endogenous to the AAV genome, and are imperative for proper packaging 
of the genome into the AAV capsid. After this cloning, the newly made AAV plasmids would be 
sent to the virus core for AAV production. 
4.4 In Vivo Experiments for DMD HITI Editing 
 After the production of AAV is complete, experiments testing the in vivo efficacy would 
be warranted. To begin, intramuscular injection of the dual-AAV vectors would be done on the 
humanized DMD mouse model to check for initial efficacy. This would be accomplished by a 
combination of RT-PCR, western blotting, and immunofluorescence to check for correction of 
proper mRNA expression, dystrophin expression, and proper dystrophin localization 
respectively, in the muscles that were injected. The dual-AAV vectors would then be 
systemically injected to check the universal efficacy with the same experiments being run as 
above, except with multiple different muscle groups including the heart and diaphragm, two of 





 This study established the ability of CRISPR/Cas9 used with the HITI methodology to be 
applied to large replacements of genomic DNA, which has previously not been explored. By 
establishing this precedent for such large replacements, the groundwork is set for a future DMD 
therapy that has the potential to restore full-length dystrophin to a vast cohort of patients with 
diverse mutations. This methodology also boasts the ability to provide gene correction to those 
patients that previously had no hope for this type of therapy. The combined positive effects of 
this therapy are much needed in the field, as there is not a single therapy that has the potential 
to reach as many patients as this one does. Not only that, but this also expands the scope of the 
gene editing toolbelt as well, showing it is possible to replace large segments of genomic DNA. 
This methodology could potentially be used to treat other complex genetic diseases that were 
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